Vicore Pharma Holding AB (publ)

Research Vicore Pharma Holding AB (publ) (VICO) on Bullrun: market cap SEK 3.29B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerVICO
ExchangeST
CountrySweden
SectorHealthcare
IndustryBiotechnology
CurrencySEK
Market capSEK 3.29B
Financial periodQ1 2026
RevenueSEK 602.00K
Net income-SEK 108.62M
Free cash flow-SEK 117.64M
Gross margin100.0%

Valuation Snapshot

latest market cap is SEK 3.29B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	SEK 3.82M	-SEK 477.47M	n/a	100.0%	n/a	SEK 578.15M	n/a	SEK 1.10B
FY2023	n/a	-SEK 310.94M	n/a	n/a	n/a	SEK 333.62M	n/a	n/a
FY2022	n/a	-SEK 288.42M	n/a	n/a	n/a	SEK 256.80M	n/a	n/a

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-14	SEK 3.29B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Related stock research

Sweden stocks Sweden Healthcare stocks A-Z stock index

Other Healthcare stocks

Camurus AB (0RD1) Flerie AB (publ) (1NP1) GENOVIS AB SE-40 (5GV) Fluicell AB (publ) (5J90) ExpreS2ion Biotech Holding AB (publ) (5JD0) ALZINOVA AB (78D) 7AL0 (7AL0) ASCELIA PHARMA AB (7ZA) Biosergen AB (8N10) ABERA BIOSCIENCE AB (8WK) Ascelia Pharma AB (publ) (ACE) AcouSort AB (ACOU)

Frequently asked questions

What is Vicore Pharma Holding AB (publ)'s market cap?

Vicore Pharma Holding AB (publ)'s market capitalization is SEK 3.29B.